MALVERN, Pa.--(BUSINESS WIRE)--Progenra, Inc. announced today it has entered in to a research collaboration with Dr. Toshihiro Nakajima, Professor, Institute of Medical Science, Tokyo Medical University. Professor Nakajima discovered the Rheumatoid Arthritis (RA) biomarker and therapeutic target Synoviolin/Hrd1, a ubiquitin E3 ligase overexpressed in RA patients; it is believed Synoviolin inhibition will be therapeutically beneficial. Under the collaboration, Progenra will work with Professor Nakajima to bring existing inhibitors to market and to utilize Progenra’s UbiPro™ Drug Discovery Platform to identify additional inhibitors.